Shanghai Cell Therapy Group Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 1,144

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 14

Shanghai Cell Therapy Group General Information

Description

Developer of tumour immune cell therapy treatments. The company operates a cellular diagnosis center and provides immune cell research and treatment services. The company is involved in cellular cold storage, cellular pharmaceuticals, antibody research, enabling patients to do genetic testing and providing research data to cancer facilities.

Contact Information

Website
www.shcell.com
Formerly Known As
Shanghai Cell Therapy Engineering Technology Research Center Co., Ltd., Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 6, No. 1585 Yuanguo Road
  • Anting Town, Jiading District
  • Shanghai, 201805
  • China
+86 400
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • Building 6, No. 1585 Yuanguo Road
  • Anting Town, Jiading District
  • Shanghai, 201805
  • China
+86 400

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shanghai Cell Therapy Group Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. IPO 30-Apr-2024 Announced Generating Revenue
11. Secondary Transaction - Private 13-Dec-2023 Completed Generating Revenue
10. Later Stage VC (Series D2) 08-Feb-2022 Completed Generating Revenue
9. Later Stage VC (Series D1) 23-Mar-2021 Completed Generating Revenue
8. Secondary Transaction - Private 26-Feb-2021 Completed Generating Revenue
7. Later Stage VC (Series C2) 01-Dec-2018 Completed Generating Revenue
6. Later Stage VC (Series C1) 01-Oct-2018 Completed Generating Revenue
5. Secondary Transaction - Private 26-Jun-2018 Completed Generating Revenue
4. Early Stage VC (Series B2) 08-Nov-2017 $9.1M $58.4M Completed Generating Revenue
3. Early Stage VC (Series B1) 18-Apr-2016 $28.5M $49.4M Completed Generating Revenue
To view Shanghai Cell Therapy Group’s complete valuation and funding history, request access »

Shanghai Cell Therapy Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of tumour immune cell therapy treatments. The company operates a cellular diagnosis center and provides immune
Biotechnology
Shanghai, China
1,144 As of 2023

Suzhou, China
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shanghai Cell Therapy Group Competitors (35)

One of Shanghai Cell Therapy Group’s 35 competitors is CureGenetics, a Venture Capital-Backed company based in Suzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CureGenetics Venture Capital-Backed Suzhou, China
NeoX Biotech Venture Capital-Backed Beijing, China
Mabworks Biotech Venture Capital-Backed Beijing, China
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Xenetic Biosciences Corporation Framingham, MA
You’re viewing 5 of 35 competitors. Get the full list »

Shanghai Cell Therapy Group Patents

Shanghai Cell Therapy Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026145457-A1 Truncated transposase, transposon system, and use thereof Pending 30-Dec-2024
WO-2026139059-A1 Polynucleotide for enhancing polypeptide expression, and nucleic acid construct and use thereof Pending 26-Dec-2024
WO-2026139087-A1 Polynucleotide for enhancing polypeptide expression, and nucleic acid construct and use thereof Pending 26-Dec-2024
WO-2026109027-A1 Multispecific antigen-binding molecule and use thereof Pending 22-Nov-2024
WO-2026082016-A1 Chimeric promoter having high activity in activated immune cells Pending 14-Oct-2024 C12N15/113
To view Shanghai Cell Therapy Group’s complete patent history, request access »

Shanghai Cell Therapy Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shanghai Cell Therapy Group Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Xiyang Investment Venture Capital Minority
CCB International PE/Buyout Minority
Jiangsu Jiuzhou Venture Capital Management Growth/Expansion Minority
Shanghai Shengshi Capital Management Growth/Expansion Minority
China Pacific Life Insurance Asset Manager Minority
You’re viewing 5 of 14 investors. Get the full list »

Shanghai Cell Therapy Group FAQs

  • When was Shanghai Cell Therapy Group founded?

    Shanghai Cell Therapy Group was founded in 2013.

  • Where is Shanghai Cell Therapy Group headquartered?

    Shanghai Cell Therapy Group is headquartered in Shanghai, China.

  • What is the size of Shanghai Cell Therapy Group?

    Shanghai Cell Therapy Group has 1,144 total employees.

  • What industry is Shanghai Cell Therapy Group in?

    Shanghai Cell Therapy Group’s primary industry is Biotechnology.

  • Is Shanghai Cell Therapy Group a private or public company?

    Shanghai Cell Therapy Group is a Private company.

  • What is Shanghai Cell Therapy Group’s current revenue?

    The current revenue for Shanghai Cell Therapy Group is .

  • How much funding has Shanghai Cell Therapy Group raised over time?

    Shanghai Cell Therapy Group has raised $285M.

  • Who are Shanghai Cell Therapy Group’s investors?

    Xiyang Investment, CCB International, Jiangsu Jiuzhou Venture Capital Management, Shanghai Shengshi Capital Management, and China Pacific Life Insurance are 5 of 14 investors who have invested in Shanghai Cell Therapy Group.

  • Who are Shanghai Cell Therapy Group’s competitors?

    CureGenetics, NeoX Biotech, Mabworks Biotech, Marengo Therapeutics, and Xenetic Biosciences are some of the 35 competitors of Shanghai Cell Therapy Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process